Prelude Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,940	Closed	-$223K	–	1196
2025 Q2	$223K	Buy	+15,940	New	+$224K	0.02%	754
2024 Q3	–	Sell	-10,343	Closed	-$240K	–	1353
2024 Q2	$240K	Sell	10,343 -26	-0.3%	-$499	0.02%	905
2024 Q1	$213K	Buy	10,369 +25	+0.2%	+$470	0.01%	1077
2023 Q4	$222K	Buy	10,344 +40	+0.4%	+$792	0.02%	899
2023 Q3	$213K	Sell	10,304 -335	-3%	-$8.5K	0.02%	867
2023 Q2	$314K	Sell	10,639 -700	-6%	-$19.7K	0.03%	621
2023 Q1	$261K	Buy	11,339 +3,996	+54%	+$110K	0.02%	712
2022 Q4	$204K	Buy	+7,343	New	+$218K	0.01%	961
2022 Q1	–	Sell	-9,610	Closed	-$429K	–	1953
2021 Q4	$429K	Buy	9,610 +3,598	+60%	+$170K	0.02%	1110
2021 Q3	$303K	Buy	6,012 +1,029	+21%	+$58K	0.02%	1131
2021 Q2	$391K	Buy	+4,983	New	+$308K	0.02%	1072
2021 Q1	–	Sell	-2,950	Closed	-$247K	–	1654
2020 Q4	$247K	Sell	2,950 -6,150	-68%	-$372K	0.02%	1010
2020 Q3	$326K	Sell	9,100 -1,809	-17%	-$54.5K	0.05%	533
2020 Q2	$264K	Buy	+10,909	New	+$256K	0.04%	653
2019 Q2	–	Sell	-4,229	Closed	-$98K	–	1802
2019 Q1	$98K	Buy	4,229 +2,252	+114%	+$47.1K	0.01%	936
2018 Q4	$41K	Buy	+1,977	New	+$35.9K	﹤0.01%	1150